PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc., a pioneer in ear, nose and throat (ENT) surgical interventions. The addition of Acclarent's innovative product portfolio expands the breadth of Integra’s market-leading brands and provides immediate scale and accretive growth via a dedicated sales channel.

新泽西州普林斯顿，2024年4月1日（环球通讯社）--全球领先的医疗技术公司Integra LifeSciences Holdings Corporation（NASDAQ:IART）今天宣布，它已成功完成对耳鼻喉（ENT）手术干预先驱Accarrent，Inc.的收购。Acclarent创新产品组合的增加扩大了Integra市场领先品牌的广度，并通过专用销售渠道提供即时规模和增值增长。

The acquisition adds $1 billion to the total addressable market of the Company’s offerings, while providing unique market opportunities for access to the attractive ENT device segment..

此次收购为该公司产品的总目标市场增加了10亿美元，同时为进入有吸引力的耳鼻喉科设备市场提供了独特的市场机会。。

“Acclarent’s strong commercial capabilities, R&D expertise, advanced portfolio and deep clinical knowledge will be important assets to Integra, enabling us to deliver transformative technologies to restore patients’ lives,” said Mike McBreen, executive vice president and president, Codman Specialty Surgical division.

Codman Specialty Surgical division执行副总裁兼总裁Mike McBreen表示：“Acclarent强大的商业能力、研发专业知识、先进的产品组合和深入的临床知识将成为Integra的重要资产，使我们能够提供变革性技术来恢复患者的生活。”。

“We are looking forward to working alongside our Acclarent colleagues to make a profound impact on ENT and neurosurgery care.”.

“我们期待着与我们备受赞誉的同事合作，为耳鼻喉科和神经外科护理产生深远影响。”。

The company will release its first quarter 2024 financial results and provide second quarter and full-year guidance, inclusive of the Acclarent business, on Thursday, April 25, 2024, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m.

该公司将于2024年4月25日（星期四）开市前发布2024年第一季度财务业绩，并提供第二季度和全年指导，包括备受赞誉的业务。在发布收益的同时，Integra的管理团队将于上午8:30召开电话会议。

ET..

等。。

A live webcast will be available on investor.integralife.com. To join the live conference call, please register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be posted on the investor section of the Company’s website following the call..

将在investor.integralife.com上进行在线直播。要参加现场电话会议，请在此处注册以接收拨入详细信息和个人pin。虽然不需要，但建议在活动开始前10分钟加入。电话会议后，将在公司网站的投资者部分发布电话会议的网络广播重播。。

About Integra LifeSciences

关于Integra LifeSciences

At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands that include Acclarent®, AmnioExcel®, Aurora®, Bactiseal®, BioD™, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®, DuraSorb®, Gentrix®, ICP Express®, Integra®, Licox®, MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®, NeuraGen®, NeuraWrap™, PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®.

在Integra LifeSciences，我们的目标是恢复患者的生活。我们创新治疗途径以提高患者预后，并制定手术，神经和再生护理的新标准。我们提供全面的高品质领先品牌组合，包括Acclarent®、AnmioExcel®、Aurora®、Bactiseal®、BioD™、Cereflo®、CereLink®Certas®Plus、Codman®、CUSA®、Cytal®、DuraGen®、DuraSeal®、DuraSorb®、Gentrix®、ICP Express®、Integra®、Licox®、MAYFIELD®、MediHoney®、MicroFrance®、MicroMatrix®、NeuraGen®、NeuraWrap™、PriMatrix®、SurgiMend®、TCC-EZ®和VersaTru®。

For the latest news and information about Integra and its products, please visit www.integralife.com..

有关Integra及其产品的最新新闻和信息，请访问www.integralife.com。。

Forward Looking Statements

前瞻性声明

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明，涉及风险和不确定性，并反映了公司截至本新闻稿发布之日的判断。除历史事实陈述外，所有陈述均为可被视为前瞻性陈述的陈述。

Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” “forecast,” “guidance,” “plan,” “anticipate,” “target,” or “continue,” the negative of these words, other terms of similar meaning or they may use future dates.

其中一些前瞻性陈述可能包含“将”、“相信”、“可能”、“可能”、“会”、“可能”、“可能”、“应该”、“期望”、“打算”、“预测”、“指导”、“计划”、“预期”、“目标”或“继续”等词语，这些词语的否定词，其他具有类似含义的术语，或者它们可能使用未来日期。

Forward-looking statements contained in this news release include, but are not limited to, statements concerning the (i) plans and objectives of management for the operation of the Company, (ii) the anticipated financial impact of the acquisition on the Company’s operating results, (iii) the anticipated benefits to the Company arising from the completion of the acquisition, and (iv) the impact of the acquisition on the Company’s business strategy and future business and operational performance.

本新闻稿中包含的前瞻性声明包括但不限于以下声明：（i）公司经营管理计划和目标；（ii）收购对公司经营成果的预期财务影响；（iii）收购完成后对公司产生的预期收益；以及（iv）收购对公司经营战略和未来业务及经营业绩的影响。

It is important to note that the Company’s goals and expectations are not predictions of actual performance and no forward-looking statement can be guaranteed. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results, including the possibility that any of the anticipated benefits of the acquisition will not be realized or will not be realized within the expected time period.

重要的是要注意，公司的目标和期望不是对实际绩效的预测，也不能保证前瞻性陈述。此类前瞻性陈述涉及风险和不确定性，可能导致实际结果与预测或预期结果存在重大差异，包括收购的任何预期收益无法实现或无法在预期时间内实现的可能性。

Such risks and uncertainties include, but are not limited, to the following: the Company’s ability to successfully integrate Acclarent and other acquire.

此类风险和不确定性包括但不限于以下方面：公司成功整合Accurarent和其他收购的能力。

These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

这些前瞻性声明仅在本协议签署之日作出，公司没有义务更新或修订前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。

CONTACTS:

联系人：

Investor Relations:

投资者关系：

Chris Ward

克里斯·沃德

(609) 772-7736

(609) 772-7736

chris.ward@integralife.com

chris.ward@integralife.com

Media:

媒体：

Laurene Isip

劳伦·伊西普

(609) 208-8121

(609) 208-8121

laurene.isip@integralife.com

laurene.isip@integralife.com